Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

JAMA

Volumn 287, Issue 7, 2002, Pages 847-857

  Barrett Connor, Elizabeth ^a   Grady, Deborah ^b   Sashegyi, Andreas ^b,c   Anderson, Pamela W ^c   Cox, David A ^c   Hoszowski, Krzysztof ^d   Rautaharju, Pentti ^e   Harper, Kristine D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Central Railway Hospital Warsaw   (Poland)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIPID; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0037138787     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.7.847     Document Type: Article

References (33)

1. Cardiovascular disease in women
2. Hormone replacement therapy, heart disease, and other considerations
3. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
4. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
5. Early risk of cardiovascular events after commencing hormone replacement therapy
6. A clinical trial of estrogen-replacement therapy after ischemic stroke
7. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
8. Value of druglicensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease
9. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: A prospective, observational study
10. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy
11. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
12. The effect of raloxifene on risk of breast cancer in postmenopausal women
13. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
14. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene
15. Postmenopausal hormone therapy increases risk for venous thromboembolic disease
16. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
17. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
18. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
19. Randomized, double-blind, placebo controlled study on the effects of raloxifene and hormone replacement therapy on plasma nitric oxide concentrations, endothelin-1 levels and endothelium-dependent vasodilation in postmenopausal women
20. Design and methods of the Raloxifene Use for The Heart (RUTH) study
21. NOVACODE serial ECG classification system for clinical trials and epidemiologic studies
22. The NOVACODE criteria for classification of ECG abnormalities and their clinically significant progression and regression
23. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
24. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: The Women's Health Study
25. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
26. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
27. The HERS trial results: Paradigms lost?
28. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial
29. Effect of postmenopausal hormones on inflammation-sensitive proteins: The postmenopausal Estrogen/Progestin interventions (PEPI) study
30. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect
31. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management